A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant
A Phase Ib Treatment Trial Using AbGn-168H to Treat Steroid Refractory Acute Graft-vs.-Host Disease (aGVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Sponsor: AbGenomics B.V Taiwan Branch
Terminated
Re-initiate a new trial per the discussion with FDA
Other terminated trials from AbGenomics B.V Taiwan Branch
More terminations from AbGenomics B.V Taiwan Branch
A PHASE1 clinical study on Acute Graft Versus Host Disease, this trial is terminated or withdrawn. The trial is conducted by AbGenomics B.V Taiwan Branch and has accumulated 7 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Apr 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2017 [monthly]
Suspended PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbGenomics B.V Taiwan Branch
For direct contact, visit the study record on ClinicalTrials.gov .